Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors

L.C. AIMLER, A.D. GODDARD, AND K.J. HILLAN
Development Sciences, Genentech, Inc., South San Francisco, California 94080

Erlotinib and gefitinib are small-molecule inhibitors of the epidermal growth factor tyrosine kinase. Erlotinib is approved for the treatment of locally advanced or metastatic non-small-cell lung cancer after failure of at least one prior chemotherapy regi-

men. Although it is active in unselected patients, clinical characteristics and tumor molecular markers associated with en-
hanced benefit have been identified. Notably, never-smoker status or a positive EGFR FISH test has been consistently pro-
ductive of greater erlotinib benefit. Other markers, such as EGFR mutations and EGFR protein expression, as determined by immunohistochemistry, and KRAS mutation status have not proven to be consistently associated with differential benefit.

The epidermal growth factor receptor (EGFR) is a re-

ceptor tyrosine kinase expressed in the majority of non-

small-cell lung cancers (NSCLC) (Dazzi et al. 1989; Kaseda et al. 1989). The efficacy of EGFR tyrosine kinase inhibitors (EGFR TKIs) in preclinical tumor models, to-

gether with their favorable toxicity profiles, led to their clinical development in NSCLC and other solid tumors (Higgins et al. 2004). Erlotinib and gefitinib are small-
molecule inhibitors of the EGFR tyrosine kinase, which showed evidence of antitumor activity in patients with NSCLC as single agents (Lynch et al. 2004b). This activ-

ity was recently shown to translate to a significant survival benefit in a randomized phase III trial of erlotinib versus placebo (hazard ratio [HR] = 0.73) in second-third-line NSCLC (Shepherd et al. 2005), whereas gefitinib failed to
demonstrate a significant survival advantage in a trial of similar design (HR = 0.89) (Tamura and Fukuoka 2005). Erlotinib’s survival advantage in second-third-line lung cancer was observed in an unselected patient population. However, it is possible that some patient subpopula-
tions might derive greater benefit than others. Indeed, one hypothesis would be that patients whose tumors are most dependent on EGFR signaling for growth and survival would derive greatest therapeutic benefit, whereas pa-
tients with tumors that are functionally independent of EGFR would not derive benefit. In this review, we exam-

ine the molecular and clinical markers that have been shown to be associated with outcome in NSCLC patients treated with EGFR TKIs and we discuss how these are re-
lated to tumor dependence on signaling through EGFR.

EGFR MUTATIONS PREDICT FOR RESPONSE FROM EGFR TKI THERAPY, BUT HAVE NOT BEEN ASSOCIATED WITH PROLONGED SURVIVAL

Somatic mutations in the tyrosine kinase domain of EGFR were recently described in tumors of NSCLC pa-
tients who showed objective clinical responses (tumor shrinkage) to erlotinib (Pao et al. 2004) and gefitinib

(Lynch et al. 2004a; Paez et al. 2004) monotherapy. Pa-
tients with EGFR-mutant tumors were more likely to be

never-smokers, females, and of Asian ethnicity (Lynch et

al. 2004a). The frequency of heterozygous mutations varies according to the population being studied but has
been reported to be approximately 10–12% in patients from the United States and 19–26% in patients from Southeast Asia.

The most frequently observed mutations are in exons
19–22 of the EGFR gene, with approximately 90% being
either in-frame deletions in exon 19 or a L858R substitu-
tion in exon 21 (Pao et al. 2004). Functional analysis of the
mutant receptors in cell lines shows evidence of specific
gain of function, with elevated ligand-dependent activa-
tion of the receptor. Furthermore, the mutants were inhib-

ited by lower concentrations of gefitinib and erlotinib compared with wild-type EGFR (Lynch et al. 2004a; Paez
et al. 2004; Pao and Miller 2005). Thus, EGFR mutations appear to define tumors that are dependent on EGFR sig-

naling and that are responsive to EGFR inhibition.

Compared to wild-type EGFR, the mutant EGFR re-

spectively activates the Akt and STAT signaling path-

ways, which support cell survival, but has no effect on
ERK signaling, which induces cell proliferation (Sor-
della et al. 2004). Consistent with this observation,
NSCLC cells expressing mutant EGFR undergo apopto-
sis upon treatment with EGFR TKIs, suggesting that mu-
tant EGFRs selectively support tumor cell survival, on
which NSCLCs become dependent. This could account for the higher frequency of objective tumor responses seen in patients with mutant EGFR-bearing tumors upon treatment with an EGFR TKI.

In a Korean study of 90 consecutive NSCLC patients treated with gefitinib monotherapy, the response rate was
14% (10/73) in EGFR wild type and 65% (11/17) in EGFR mutant tumors, respectively. Of patients who re-
sponded, 48% were EGFR wild type and 52% were EGFR mutant (Han et al. 2005). A similar observation has been made in patients who respond to erlotinib (John-
son et al. 2004; Pao et al. 2004).
The impact of EGFR mutations on survival has been analyzed retrospectively in samples from three randomized trials. Two of these were negative trials (TRIBUTE/erlotinib [Eberhard et al. 2005] and INTACT-2/gefitinib [Bell et al. 2005a]), where an EGFR TKI was combined with chemotherapy in first-line lung cancer therapy. In both trials there were increased tumor response rates in patients with EGFR mutant tumors that were in the EGFR TKI treatment arm (statistically significant in TRIBUTE and a trend in INTACT-2). However, there was no evidence of a statistically significant treatment effect of mutation status on either progression-free survival or survival. In both studies, patients with EGFR mutated tumors had a better prognosis, regardless of the therapy arm. In BR.21, a monotherapy trial that showed a positive survival advantage in the overall patient population, EGFR mutation status was associated neither with an overall survival benefit, nor with a better prognosis (Tsao et al. 2005). Interestingly, data from an underpowered, and as yet unconfirmed, study suggest that specific EGFR mutations may have unique clinical characteristics, as EGFR TKI-treated patients with exon-19 deletion mutations had longer median survival than patients with the L858R point mutation (34 months versus 8 months) (Riely et al. 2006). This observation should be considered in future analysis of data from clinical trials.

Some patients with tumors bearing EGFR mutations, who have progressed on erlotinib or gefitinib therapy, have been shown to contain an additional EGFR mutation. This secondary mutation in exon 20 leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain (Pao et al. 2005a). An analogous mutation (T315I) has been observed in the ABL kinase in association with acquired resistance to imatinib (Branford et al. 2002), suggesting that this may be a common therapy-selected EGFR TKI escape mechanism in tumors with activating mutations in the tyrosine kinase domain. The emergence of additional mutations on therapy suggests the tumor is dependent on activation of the EGFR pathway for survival and growth. Interestingly, susceptibility to inhibition of NSCLC may be associated with the germline transmission of the T790M mutation, suggesting that altered EGFR signaling is also important in the genetic susceptibility to lung cancer (Bell et al. 2005a).

### Table 1. Predictive Value of IHC for a Survival Benefit in BR.21, TRIBUTE, and ISEL

<table>
<thead>
<tr>
<th></th>
<th>BR.21</th>
<th>TRIBUTE</th>
<th>ISEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects</td>
<td>731</td>
<td>1079</td>
<td>1692</td>
</tr>
<tr>
<td>Number of patients tested</td>
<td>324 (44.6%)</td>
<td>344 (31.9%)</td>
<td>379 (22.4%)</td>
</tr>
<tr>
<td>HR for overall survival</td>
<td>0.73 (95% CI = 0.61–0.86)</td>
<td>1.00 (95% CI = 0.86–1.16)</td>
<td>0.68 (95% CI = 0.56–1.08)</td>
</tr>
<tr>
<td>All subjects</td>
<td>0.73 (95% CI = 0.61–0.86)</td>
<td>1.00 (95% CI = 0.86–1.16)</td>
<td>0.68 (95% CI = 0.56–1.08)</td>
</tr>
<tr>
<td>IHC positive</td>
<td>0.68 (95% CI = 0.49–0.94)</td>
<td>1.27 (95% CI = 0.95–1.71)</td>
<td>0.77 (95% CI = 0.56–1.08)</td>
</tr>
<tr>
<td>IHC negative</td>
<td>0.93 (95% CI = 0.63–1.36)</td>
<td>1.02 (95% CI = 0.54–1.95)</td>
<td>1.57 (95% CI = 0.86–2.87)</td>
</tr>
</tbody>
</table>
Analysis of response rate in NSCLC patients with either erlotinib or gefitinib suggests that KRAS mutations were associated with a lack of tumor regression (Pao et al. 2005b). Retrospective analysis of tumor tissues from 264 (25%) of the patients in TRIBUTE suggests that patients with KRAS mutant tumors experience worse survival when erlotinib was combined with chemotherapy (HR = 2.06; 95% CI = 1.11–3.80), compared with those treated with chemotherapy alone (HR = 1.05; 95% CI = 0.73–1.50). This negative interaction appears to be related to expression of EGFR, because in patients in whom both EGFR IHC and KRAS mutation status were available, there was a significant association with poor outcome in patients with KRAS mutant tumors that expressed EGFR (Table 2).

Analysis of response rate in NSCLC patients with either erlotinib or gefitinib suggests that KRAS mutations were associated with a lack of tumor regression (Pao et al. 2005b). Retrospective analysis of tumor tissues from 264 (25%) of the patients in TRIBUTE suggests that patients with KRAS mutant tumors experience worse survival when erlotinib was combined with chemotherapy (HR = 2.06; 95% CI = 1.11–3.80), compared with those treated with chemotherapy alone (HR = 1.05; 95% CI = 0.73–1.50). This negative interaction appears to be related to expression of EGFR, because in patients in whom both EGFR IHC and KRAS mutation status were available, there was a significant association with poor outcome in patients with KRAS mutant tumors that expressed EGFR (Table 2).

**Table 2.** Association of KRAS Mutations and EGFR IHC with Survival in TRIBUTE

<table>
<thead>
<tr>
<th>KRAS mutation and EGFR expression by IHC</th>
<th>Erlotinib + chemo</th>
<th>Chemo alone</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFR IHC−</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>Median OS (mo) (95% CI)</td>
<td>9.6</td>
<td>0.597</td>
</tr>
<tr>
<td>Log rank p-value</td>
<td>0.001</td>
<td>0.001</td>
</tr>
<tr>
<td>EGFR IHC+</td>
<td>12</td>
<td>20</td>
</tr>
<tr>
<td>Median OS (mo) (95% CI)</td>
<td>4.9 (2.1, 11.5)</td>
<td></td>
</tr>
</tbody>
</table>
It is unclear why a negative interaction was observed when erlotinib was administered in combination with chemotherapy in patients whose tumors bore KRAS mutations. It will be important to determine whether this observation is confirmed by retrospective analysis of other randomized controlled trials. Erlotinib has been shown to prolong survival when administered in combination with gemcitabine in pancreatic cancer, a tumor where KRAS mutations are very common.

NEVER-SMOKER STATUS IS CONSISTENTLY PREDICTIVE OF GREATER PATIENT BENEFIT (SURVIVAL AND RESPONSE) FOR ERLOTINIB OR GEFITINIB MONOTHERAPY AND FOR ERLOTINIB IN COMBINATION WITH CHEMOTHERAPY

Lung cancer patients who have never smoked tobacco have consistently shown a benefit from both erlotinib and gefitinib (Table 3). This novel therapeutic observation is unique to EGFR TKIs and has been observed in phase III trials with erlotinib (BR.21) (Shepherd et al. 2005) and gefitinib (ISEL) monotherapy as well as for erlotinib in combination with chemotherapy (TRIBUTE) (Herbst et al. 2005).

Studies have suggested that tumors arising in never-smokers are molecularly and biologically distinct and may be associated with a better prognosis (Sanchez-Cespedes et al. 2001). Never-smokers are more likely to have mutations than smokers in the tyrosine kinase domain of EGFR and almost never harbor mutations in KRAS (Tam et al. 2006). In countries of Southeast Asia, lung cancer is more common in never-smokers than in smokers; thus, racial background, smoking history, and gene mutation status should be considered when designing and interpreting clinical trials in NSCLC with EGFR-TKIs.

SUMMARY AND CONCLUSIONS

Predictive molecular biomarkers for NSCLC patients treated with EGFR TKIs have largely been determined from studies of small case series and retrospective analyses of subsets of patients from randomized trials; in some cases, these were extracted from negative clinical trials. Overall, the predictive data generated to date can be summarized as follows:

1. EGFR mutations predict dramatic tumor shrinkage but have not been shown to be a good marker for the clinically meaningful endpoint of prolonged survival.
2. EGFR protein expression, as determined by IHC, predicts greater treatment benefit in BR.21 but is not a predictor of benefit in TRIBUTE.
3. High EGFR gene copy number may be the single molecular marker that is most predictive for erlotinib monotherapy.
4. KRAS mutations, which are positively associated with smoking history, select for a subset of patients who do not appear to benefit from erlotinib therapy.
5. Never-smoker status is consistently predictive of greater erlotinib benefit (survival and response) for monotherapy and in combination with chemotherapy. This and other emerging diagnostic information will aid significantly in designing future studies and, ultimately, should help physicians decide which patients will be most likely to benefit from EGFR TKIs.

ACKNOWLEDGMENTS

We thank Dr. Fred R. Hirsch of the University of Colorado Cancer Center for providing and granting permission to reproduce Figure 1.

REFERENCES


Cold Spring Harbor Laboratory Press on October 18, 2017 - Published by symposium.cshlp.org

Table 3. Summary of Survival Benefit Observed in Never-Smokers Treated with Erlotinib (BR.21 and TRIBUTE) or Gefitinib (ISEL)

<table>
<thead>
<tr>
<th></th>
<th>BR.21</th>
<th>TRIBUTE</th>
<th>ISEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects</td>
<td>731</td>
<td>1079</td>
<td>1692</td>
</tr>
<tr>
<td>Number of never-smokers</td>
<td>146 (20.0%)</td>
<td>116 (10.8%)</td>
<td>375 (22%)</td>
</tr>
<tr>
<td>HR for overall survival</td>
<td>0.73 (95% CI = 0.61–0.86)</td>
<td>1.00 (95% CI = 0.86–1.16)</td>
<td>0.49 (95% CI = 0.49–0.92)</td>
</tr>
<tr>
<td>Never-smokers</td>
<td>0.42 (95% CI = 0.28–0.64)</td>
<td>0.49 (95% CI = 0.28–0.85)</td>
<td>0.67 (95% CI = 0.37–1.16)</td>
</tr>
<tr>
<td>Current/former smokers</td>
<td>0.87 (95% CI = 0.71–1.03)</td>
<td>1.11 (95% CI = 0.94–1.29)</td>
<td>0.92 (95% CI = 0.79–1.06)</td>
</tr>
</tbody>
</table>
to lung cancer may be associated with the T790M drug resistance mutation in EGFR. J Natl Cancer Inst. 2007; 99:3472.


Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors

L.C. AMLER, A.D. GODDARD and K.J. HILLAN

Access the most recent version at doi:10.1101/sqb.2005.70.048

References
This article cites 39 articles, 16 of which can be accessed free at: http://symposium.cshlp.org/content/70/483.full.html#ref-list-1

License

Email Alerting Service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.